The Chemours Company (NYSE:CC) Receives Average Recommendation of “Hold” from Brokerages

The Chemours Company (NYSE:CC) has been assigned a consensus recommendation of “Hold” from the nine ratings firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $24.11.

CC has been the subject of several research reports. Morgan Stanley decreased their target price on Chemours from $25.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Barclays increased their target price on Chemours from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. The Goldman Sachs Group reduced their price objective on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a research report on Tuesday, January 7th. Finally, Truist Financial began coverage on Chemours in a research report on Tuesday, January 28th. They set a “buy” rating and a $27.00 price objective for the company.

Institutional Trading of Chemours

Institutional investors have recently added to or reduced their stakes in the business. Vision One Management Partners LP purchased a new stake in Chemours during the 3rd quarter valued at $28,252,000. Two Sigma Advisers LP boosted its stake in Chemours by 9.4% during the 3rd quarter. Two Sigma Advisers LP now owns 503,100 shares of the specialty chemicals company’s stock valued at $10,223,000 after purchasing an additional 43,200 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in Chemours during the 4th quarter valued at $357,000. Entropy Technologies LP purchased a new stake in Chemours during the 4th quarter valued at $266,000. Finally, Twelve Points Wealth Management LLC boosted its stake in Chemours by 42.8% during the 4th quarter. Twelve Points Wealth Management LLC now owns 78,325 shares of the specialty chemicals company’s stock valued at $1,324,000 after purchasing an additional 23,490 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Stock Down 5.6 %

Shares of NYSE:CC opened at $16.80 on Monday. Chemours has a 52-week low of $15.10 and a 52-week high of $29.83. The firm has a market capitalization of $2.51 billion, a P/E ratio of 33.59 and a beta of 1.81. The stock has a 50 day moving average price of $18.39 and a 200-day moving average price of $19.02. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.